211 related articles for article (PubMed ID: 30502651)
1. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
[TBL] [Abstract][Full Text] [Related]
2. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
3. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-κB activation.
Arunkumar N; Liu C; Hang H; Song W
Cell Mol Immunol; 2013 Jul; 10(4):360-72. PubMed ID: 23727784
[TBL] [Abstract][Full Text] [Related]
5. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
6. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells.
Abel K; Wang Y; Fritts L; Sanchez E; Chung E; Fitzgerald-Bocarsly P; Krieg AM; Miller CJ
Clin Diagn Lab Immunol; 2005 May; 12(5):606-21. PubMed ID: 15879022
[TBL] [Abstract][Full Text] [Related]
7. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses].
Li N; Fan XG; Tang SE; Zhu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582
[TBL] [Abstract][Full Text] [Related]
8. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
[TBL] [Abstract][Full Text] [Related]
9. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
10. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.
Vollmer J; Weeratna RD; Jurk M; Samulowitz U; McCluskie MJ; Payette P; Davis HL; Schetter C; Krieg AM
Immunology; 2004 Oct; 113(2):212-23. PubMed ID: 15379982
[TBL] [Abstract][Full Text] [Related]
11. A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.
Garon EB; Spira AI; Johnson M; Bazhenova L; Leach J; Cummings AL; Candia A; Coffman RL; Janatpour MJ; Janssen R; Gamelin E; Chow LQM
Clin Cancer Res; 2021 Aug; 27(16):4566-4573. PubMed ID: 34108179
[TBL] [Abstract][Full Text] [Related]
12. Species-Specific Minimal Sequence Motif for Oligodeoxyribonucleotides Activating Mouse TLR9.
Pohar J; Lainšček D; Fukui R; Yamamoto C; Miyake K; Jerala R; Benčina M
J Immunol; 2015 Nov; 195(9):4396-405. PubMed ID: 26416273
[TBL] [Abstract][Full Text] [Related]
13. The immunostimulatory effect of CpG oligodeoxynucleotides on peripheral blood mononuclear cells of healthy dogs and dogs with atopic dermatitis.
Jassies-van der Lee A; Rutten V; Spiering R; van Kooten P; Willemse T; Broere F
Vet J; 2014 Apr; 200(1):103-8. PubMed ID: 24461202
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.
Sfondrini L; Sommariva M; Tortoreto M; Meini A; Piconese S; Calvaruso M; Van Rooijen N; Bonecchi R; Zaffaroni N; Colombo MP; Tagliabue E; Balsari A
Int J Cancer; 2013 Jul; 133(2):383-93. PubMed ID: 23319306
[TBL] [Abstract][Full Text] [Related]
15. Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells.
Booth JS; Nichani AK; Benjamin P; Dar A; Krieg AM; Babiuk LA; Mutwiri GK
Vet Immunol Immunopathol; 2007 Jan; 115(1-2):24-34. PubMed ID: 17067685
[TBL] [Abstract][Full Text] [Related]
16. Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4
Gallotta M; Assi H; Degagné É; Kannan SK; Coffman RL; Guiducci C
Cancer Res; 2018 Sep; 78(17):4943-4956. PubMed ID: 29945961
[TBL] [Abstract][Full Text] [Related]
17. CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans.
Campbell JD; Cho Y; Foster ML; Kanzler H; Kachura MA; Lum JA; Ratcliffe MJ; Sathe A; Leishman AJ; Bahl A; McHale M; Coffman RL; Hessel EM
J Clin Invest; 2009 Sep; 119(9):2564-76. PubMed ID: 19726873
[TBL] [Abstract][Full Text] [Related]
18. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
19. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.
Yu D; Putta MR; Bhagat L; Dai M; Wang D; Trombino AF; Sullivan T; Kandimalla ER; Agrawal S
Antimicrob Agents Chemother; 2008 Dec; 52(12):4320-5. PubMed ID: 18852281
[TBL] [Abstract][Full Text] [Related]
20. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.
Pradhan P; Qin H; Leleux JA; Gwak D; Sakamaki I; Kwak LW; Roy K
Biomaterials; 2014 Jul; 35(21):5491-504. PubMed ID: 24720881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
